SBP GROUP(01177)

5.260+0.0000.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation
  Reuters · 09-01 16:53
  Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation
- SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout
  Bulletin Express · 09-01 10:22
  SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout
- Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug
  MT Newswires Live · 08-31 20:47
  Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug
- SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC
  Stock News · 08-31 18:54
  SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC
- Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million
  Reuters · 08-31 18:40
  Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million
- Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets
  THOMSON REUTERS · 08-31 18:39
  Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets
- Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties
  THOMSON REUTERS · 08-31 18:39
  Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties
- Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate
  Reuters · 08-31 18:16
  Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate
- Sino Biopharmaceutical Stock Sheds 2.6% in Hong Kong
  Dow Jones · 08-31 16:33
  Sino Biopharmaceutical Stock Sheds 2.6% in Hong Kong
- Movement Alert｜SBP GROUP Falls 3.04% in Regular Trading, Trading at HK$5.425
  Market Focus · 08-31 09:55
  Movement Alert｜SBP GROUP Falls 3.04% in Regular Trading, Trading at HK$5.425
- SBP Group Unveils Phase I Data: Single-Dose Kylo-11 Achieves Up to 97% Sustained Lp(a) Reduction
  Bulletin Express · 08-31 08:22
  SBP Group Unveils Phase I Data: Single-Dose Kylo-11 Achieves Up to 97% Sustained Lp(a) Reduction
- SBP Group Secures NMPA and FDA Green Lights for LM-364 “Nectin-4TME ADC” Clinical Trials
  Bulletin Express · 08-28
  SBP Group Secures NMPA and FDA Green Lights for LM-364 “Nectin-4TME ADC” Clinical Trials
- Sino Biopharm Wins NMPA Nod to Start LM-364 Nectin-4 TME ADC Trial in Solid Tumors
  Reuters · 08-28
  Sino Biopharm Wins NMPA Nod to Start LM-364 Nectin-4 TME ADC Trial in Solid Tumors
- Sino Biopharmaceutical - Lm-364 'Nectin-4Tme ADC' Receives Nmpa Clinical Trial Approval for Advanced Solid Tumors
  THOMSON REUTERS · 08-28
  Sino Biopharmaceutical - Lm-364 'Nectin-4Tme ADC' Receives Nmpa Clinical Trial Approval for Advanced Solid Tumors
- Movement Alert｜SBP GROUP Falls 3.05% in Regular Trading, Trading at HK$5.545
  Market Focus · 08-27
  Movement Alert｜SBP GROUP Falls 3.05% in Regular Trading, Trading at HK$5.545
- China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval
  Deep News · 08-26
  China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval
- Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
  Dow Jones · 08-26
  Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
- Movement Alert｜SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval
  Market Focus · 08-26
  Movement Alert｜SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval
- Sino Biopharma Wins FDA Clearance to Start Trial of Cpx301 GLP-1 Weight-Loss Microneedle Patch
  Reuters · 08-25
  Sino Biopharma Wins FDA Clearance to Start Trial of Cpx301 GLP-1 Weight-Loss Microneedle Patch
- Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$8.26, Keeps at Buy
  MT Newswires Live · 08-24
  Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$8.26, Keeps at Buy
Company Profile
Company Name
SBP GROUP
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.sinobiopharm.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
- 08-19
  Interim Report
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- 04-29
  Annual Report
  2025 ANNUAL REPORT
  2025 ANNUAL REPORT

1D
5D
Day
Week
Month

Loading ...

High

5.295

Open

5.295

Volume%

0.43

Low

5.190

5.260

T/O Rate

0.22%

To The Moon

SBP GROUP(01177)

Company Profile

Most Discussed